Tous Actualités
Suivre
Abonner Boehringer Ingelheim

Boehringer Ingelheim

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

Ingelheim, Germany (ots/PRNewswire)

  • For Non-US Media Only
  • Boehringer Ingelheim's LUX-Lung Programme Moves Forward With New Studies Revealing the Potential of BIBW 2992 in Personalising Lung Cancer Care
  • The First Presentation of Data From BIBF 1120 in Ovarian Cancer
Boehringer Ingelheim will present new data on the company's two
lead oncology compounds, BIBW 2992(i) and BIBF 1120(ii) at the 2009
Annual Meeting of the American Society of Clinical Oncology (ASCO),
the company announced today. Two studies in the LUX-Lung clinical
development programme for BIBW 2992 and a Phase II study of BIBF 1120
in ovarian cancer patients will be Presented.
(i) (planned trade name Tovok(TM))
(ii) (planned trade name Vargatef(TM))
LUX Lung 2 interim results
Interim Phase II data from the LUX-Lung 2 study suggest BIBW 2992
has anti-tumour activity in advanced second-line non-small cell lung
cancer (NSCLC) patients who have epidermal growth factor receptor
(EGFR) mutations.(1)
"Lung cancer kills more people than any other cancer.(3) The
LUX-Lung 1 and 2 studies represent an opportunity to investigate BIBW
2992 across a range of different patient populations," said Dr
Manfred Haehl, Corporate Senior Vice President Medicine at Boehringer
Ingelheim. "The preliminary data from the LUX-Lung 2 study suggests
that BIBW 2992 may have activity in the second-line setting among
NSCLC patients with EGFR mutations, which is encouraging news."(1)
BIBW 2992 is an orally administered irreversible dual inhibitor of
the epidermal growth factor receptor (EGFR) and human epithelial
receptor 2 (HER2) tyrosine kinases.(4) It is the first irreversible
EGFR-TKI (tyrosine kinase inhibitor) to reach Phase III for
third/fourth-line NSCLC.(5)
In the emerging era of personalised cancer medicine, Boehringer
Ingelheim is one of the first companies to prospectively identify
appropriate patients for clinical trials based on biomarkers. As part
of the LUX-Lung clinical development programme, Boehringer Ingelheim
is evaluating BIBW 2992 in NSCLC patients who test positive for EGFR
activating mutations.
"It is well documented that 'activating' mutations that arise in
the tyrosine kinase (TK) domain of the EGFR gene are associated with
an increased sensitivity to first generation EGFR TKIs.(6,7,8) The
majority of patients who initially respond to EGFR TKIs such as
gefitinib or erlotinib will eventually develop resistance, often
through gaining another mutation, such as the so-called T790M
resistance mutation,"(9,10) said Dr Haehl.
Detailed Findings from LUX-Lung 2:(1)
To date, 409 NSCLC patients have been screened in the LUX-Lung 2
study and 104 patients with EGFR mutations have started treatment
with BIBW 2992 once daily. Preliminary data will be presented at ASCO
for the first 73 second line patients, all of whom had previously
received one regimen of chemotherapy. 67 patients are evaluable for
response.
Interim data show: (1)
  • 64% of patients (43/67) taking BIBW 2992 in the 2nd line setting experienced a partial response (75% among patients with deletion 19 and 66% in patients with L858R mutations)
  • 31% (21/67) of patients taking BIBW 2992 in the 2nd line setting experienced stable disease
  • Median progression-free survival (PFS) in 2nd line setting is 10.2 months
  • The most common related adverse events were diarrhoea and skin-related disorders in 86% and 89% of patients respectively [16% and 18% being grade 3 respectively]
  • 37 patients had dose reduction and 4 patient discontinued treatment due to adverse events
Findings from LUX Lung 1
In addition, preliminary data on the demographic and blinded
safety data from the ongoing Phase III study, the LUX-Lung 1 trial,
will be presented at ASCO for the first time.(11)
The LUX-Lung 1 study addresses a critical need for treatment
options for NSCLC patients after failure with a second-line or
third-line reversible EGFR inhibitor (i.e. erlotinib or gefitinib).
This study recently moved from Phase IIb into Phase III.(11)
"The LUX-Lung 1 study is important as it investigates BIBW 2992
in a Group of patients for whom there are no other approved treatment
options. These are patients who have already been through standard
first-line or second-line chemotherapy and then received treatment
with an EGFR TKI. The LUX-Lung 1 study will evaluate whether BIBW
2992 will extend the lives of these cancer patients."(11) said Dr
Haehl.
First presentation of Phase II data for BIBF 1120 in ovarian
cancer
Data from a Phase II study of BIBF 1120 in patients with ovarian
cancer who responded to at least second-line chemotherapy will be
presented at ASCO in Orlando. The study showed a potential delay in
disease progression: with BIBF 1120 the median time to RECIST
progression was 4.8, and 2.8 for placebo.(2) BIBF 1120 is an oral
compound that works by simultaneously inhibiting vascular endothelial
growth factor receptors (VEGFRs), platelet-derived growth factor
receptors (PDGFRs) and fibroblast growth factor receptors (FGFRs) -
all factors which are crucially involved in the formation of blood
vessels, a process known as angiogenesis.(12,13)
"There is a great need for more effective and well tolerated
treatment options for women with ovarian cancer. We have a growing
body of evidence that anti-angiogenic agents may represent an
important treatment approach for this disease," commented Prof.
Jonathan A Ledermann, MD, Professor of Medical Oncology & Director at
the Cancer Research UK & UCL Cancer Trials Centre, University College
London. "These data indicate BIBF 1120 may have a potential role in
delaying disease progression in patients with ovarian cancer who had
previously responded to chemotherapy."
Because angiogenesis plays a pivotal role in the growth of solid
tumours,(13) BIBF 1120 is currently being investigated in a number of
cancer types including advanced NSCLC. The LUME-Lung Phase III
clinical trial programme is investigating BIBF 1120 in combination
with standard second-line chemotherapy treatments for patients with
advanced NSCLC. Approximately 2,600 patients will be enrolled, making
this one of the largest Phase III study programmes in this NSCLC
patient population to date.
    For Non-US Journalists Only
    Boehringer Ingelheim Oncology: A podcast update from ASCO 2009
               Available from Saturday 16th May 2009
    Visit http://www.personalisingcancercare.com to find out more about
    Boehringer Ingelheim's compounds and watch experts Dr. James Spicer and
    Dr. Rolf Kaiser discuss the significance of these exciting trial results.
Notes to editors
About Lung Cancer
Lung cancer is the world's most common cancer and kills more
people than any other cancer. (3,14) In 2008, approximately 1.52
million new cases of lung cancer were diagnosed worldwide, with 1.31
million people dying from the disease.(14) In the United States, an
estimated 161,840 deaths, accounting for 29 percent of all cancer
deaths, occurred in 2008, according to the American Cancer Society
(ACS).(15)
About Ovarian Cancer
According to the 2008 World Health Organization World Cancer
Report, as of 2002, ovarian cancer was ranked as the 6th most common
cancer in women. Additionally, approximately 204,000 new cases were
diagnosed worldwide and 125,000 women died from the disease in
2002.(14) The ACS estimates that about 21,650 new cases of ovarian
cancer were diagnosed in the United States (U.S.) during 2008. Only
forty-five percent of women with ovarian cancer are still alive at
least five years after diagnosis in the U.S.(16)
About Boehringer Ingelheim in Oncology
Building on scientific expertise and excellence in the fields of
pulmonary and cardiovascular medicine, metabolic disease, neurology,
virology and immunology, Boehringer Ingelheim has embarked on a major
research programme to develop innovative cancer drugs. Working in
close collaboration with the international scientific community and a
number of the world's leading cancer centres, Boehringer Ingelheim is
committed to discovering and developing novel cancer treatments. This
commitment is underpinned by using advances in science to develop a
range of targeted therapies in areas of medical need, including
various solid tumours and haematological cancers.
The current focus of research includes compounds in three areas:
angiogenesis inhibition, signal transduction inhibition and
cell-cycle kinase inhibition. BIBW 2992 entered Phase IIb/III
clinical development in NSCLC earlier in 2008 and was granted Fast
Track designation for a third/fourth line treatment indication in
NSCLC by the US Food & Drug Administration. In addition, the
LUME-Lung Phase III clinical trial programme, which is investigating
BIBF 1120 in combination with standard second-line chemotherapy
treatments for patients with advanced NSCLC, is currently ongoing. In
the area of cell-cycle kinase inhibition, Boehringer Ingelheim is
developing inhibitors of polo-like kinase 1 (Plk1), a protein that is
involved in the processes of cell division. These molecules are in
the early stages of clinical development.
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading
pharmaceutical companies. Headquartered in Ingelheim, Germany, it
operates globally with 138 affiliates in 47 countries and 41,300
employees. Since it was founded in 1885, the independent,
family-owned company has been committed to researching, developing,
manufacturing and marketing novel products of high therapeutic value
for human and veterinary medicine.
In 2008, Boehringer Ingelheim posted net sales of US$17 billion
(11.6 billion euro) while spending one-fifth of net sales in its
largest business segment, Prescription Medicines, on research and
development.
For U.S. journalists, please visit
http://us.boehringer-ingelheim.com
For journalists outside the U.S., please visit
http://www.boehringer-ingelheim.com
Note:
Please be advised this release is from Boehringer Ingelheim
Corporate Headquarters in Germany. Please be aware that there may be
national differences between countries regarding specific medical
information, including licensed uses. Please take account of this
when referring to the information provided in this document.
References
1. Shih J-Y et al. "A Phase II study of BIBW 2992, a novel
irreversible dual EGFR and HER2 tyrosine kinase inhibitor (TKI), in
patients with adenocarcinoma of the lung and activating EGFR
mutations after failure of 1 line of chemotherapy (LUX-Lung 2)."
Poster Discussion Presentation. 1 June 2009, Session Time: 8:00AM -
12:00PM. #8013
2. Ledermann, J. A. "A randomised Phase II placebo-controlled
trial using maintenance therapy to evaluate the vascular targeting
agent BIBF 1120 following treatment of relapsed ovarian cancer (OC)."
Oral presentation, Clinical Science Symposium. Monday, 1 June 2009,
Session Time 9:45AM - 11:15AM. # 5501
3. "Ask the Expert Online Q&A: Are the number of cancer cases
increasing or decreasing in the world?" 1 April 2008. World Health
Organization. 5 May 2009.
http://www.who.int/features/qa/15/en/print.html.
4. Li D et al. "BIBW2992, an irreversible EGFR/HER2 inhibitor
highly effective in preclinical lung cancer models." Oncogene
2008;27:4702-4711
5. Boehringer Ingelheim Pharmaceuticals. "BIBW 2992 and BSC
Versus Placebo and BSC in Non-Small Cell Lung Cancer Patients Failing
Erlotinib or Gefitinib (LUX-LUNG 1)" 23 April 2009.
ClinicalTrials.gov. 5 May 2009. http://clinicaltrials.gov/ct2/show/NC
T00656136?term=BIBW+2992+and+Phase+III&rank=1.
6. Lynch, T. J. et al. "Activating mutations in the epidermal
growth factor receptor underlying responsiveness of non-small-cell
lung cancer to gefitinib." N. Engl. J. Med. 350, 2129-2139 (2004).
Available at: http://content.nejm.org/cgi/reprint/350/21/2129.pdf.
Accessed on 5 May 2009.
7. Paez, J. G. et al. "EGFR mutations in lung cancer: correlation
with clinical response to gefitinib therapy." Science 304, 1497-1500
(2004). Available at: http://www.sciencemag.org/cgi/reprint/1099314v1
.pdf?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=&fulltext=egfr&searchid=
1&FIRSTINDEX=0&fdate=//&tdate=//&resourcetype=HWCIT
Accessed on 5 May 2009.
8. Pao, W. et al. "EGF receptor gene mutations are common in lung
cancers from 'never smokers' and are associated with sensitivity of
tumours to gefitinib and erlotinib." Proc. Natl Acad. Sci. USA 101,
13306-13311 (2004). Available at:
http://www.pnas.org/cgi/doi/10.1073/pnas.0405220101. Accessed on 5
May 2009.
9. Riely G. J. et al. "Clinical Course of Patients with Non
-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon19
and Exon 21 Mutations Treated with Gefitinib or Erlotinib." Clin.
Cancer Res, 12, 839-844(2006). Available at:
http://clincancerres.aacrjournals.org/cgi/reprint/12/3/839. Accessed
on 5 May 2009.
10. Balak, M. N. et al. "Novel D761Y and common secondary T790M
mutations in epidermal growth factor receptor-mutant lung
adenocarcinomas with acquired resistance to kinase inhibitors." Clin.
Cancer Res. 12, 6494-6500 (2006). Available at:
http://clincancerres.aacrjournals.org/cgi/reprint/12/21/6494.
Accessed on 5 May 2009.
11. Yang C-H et al. "Phase IIb/III double-blind randomized trial
of BIBW 2992, an irreversible, dual inhibitor of EGFR and HER2 plus
best supportive care (BSC) versus placebo plus BSC in patients with
NSCLC failing 1-2 lines of chemotherapy (CT) and erlotinib or
gefitinib (LUX-Lung1): a preliminary report. General Poster Session:
Lung Cancer - Metastatic." Saturday 30 May 2009, Session Time: 2:00PM
- 6:00PM. # 8062
12. Hilberg F. et al. "BIBF1120 a novel, small molecule triple
angiokinase inhibitor: profiling as a clinical candidate for cancer
therapy." European Journal of Cancer Supplements. 2004; 2:50.
13. Lewis J. Kleinsmith. "Understanding Cancer and Related
Topics: Understanding Angiogenesis." Rockville: National Cancer
Institute, 2006. Available at:
http://cancer.gov/cancertopics/understandingcancer. Accessed on 5 May
2009.
14. P Boyle and B Levin (eds). "World Cancer Report 2008.", World
Health Organization: International Agency for Research on Cancer.
Lyon: 2008.
15. American Cancer Society. "Cancer Facts and Figures 2008."
Atlanta: 2008. Available at:
http://www.cancer.org/downloads/STT/2008CAFFfinalsecured.pdf.
Accessed on 5 May 2009.
16. American Cancer Society. "Ovarian Cancer Detailed Guide."
Atlanta: 2008. Available at:
http://documents.cancer.org/114.00/114.00.pdf. Accessed on 5 May
2009.

Contact:

Corporate / Global Media Contact: Julia Meyer-Kleinmann, Head Science
& Technology Communications, Boehringer Ingelheim GmbH, Tel.:
+49-6132-77-8271, Mob: +49-178-2908178, Email:
press@boehringer-ingelheim.com

Plus de actualités: Boehringer Ingelheim
Plus de actualités: Boehringer Ingelheim